dipyridamole has been researched along with Multiple Sclerosis in 4 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dipyridamole is an inhibitor of microglia activation and may have a role in MS and other neurological conditions to attenuate microglial activity." | 5.39 | Reduction of microglial activity in a model of multiple sclerosis by dipyridamole. ( Hader, W; Metz, LM; Sloka, S; Starreveld, Y; Yong, VW, 2013) |
| "Dipyridamole is an inhibitor of microglia activation and may have a role in MS and other neurological conditions to attenuate microglial activity." | 1.39 | Reduction of microglial activity in a model of multiple sclerosis by dipyridamole. ( Hader, W; Metz, LM; Sloka, S; Starreveld, Y; Yong, VW, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sunke, R | 1 |
| Bankala, R | 1 |
| Thirupataiah, B | 1 |
| Ramarao, EVVS | 1 |
| Kumar, JS | 1 |
| Doss, HM | 1 |
| Medishetti, R | 1 |
| Kulkarni, P | 1 |
| Kapavarapu, RK | 1 |
| Rasool, M | 1 |
| Mudgal, J | 1 |
| Mathew, JE | 1 |
| Shenoy, GG | 1 |
| Parsa, KVL | 1 |
| Pal, M | 1 |
| Sloka, S | 1 |
| Metz, LM | 1 |
| Hader, W | 1 |
| Starreveld, Y | 1 |
| Yong, VW | 1 |
| Nosengo, N | 1 |
| Yoshikawa, M | 1 |
| Suzumura, A | 1 |
| Tamaru, T | 1 |
| Takayanagi, T | 1 |
| Sawada, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Controlled Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis[NCT02493049] | Phase 2 | 17 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for dipyridamole and Multiple Sclerosis
| Article | Year |
|---|---|
InCl
Topics: Animals; Arthritis; Cyclic Nucleotide Phosphodiesterases, Type 4; Encephalomyelitis, Autoimmune, Exp | 2019 |
Reduction of microglial activity in a model of multiple sclerosis by dipyridamole.
Topics: Adenosine Triphosphate; Animals; Cell Survival; Cells, Cultured; Culture Media, Conditioned; Cytokin | 2013 |
Can you teach old drugs new tricks?
Topics: Animals; Azoles; Bipolar Disorder; Carbazoles; Clinical Trials, Phase II as Topic; Dipyridamole; Dru | 2016 |
Effects of phosphodiesterase inhibitors on cytokine production by microglia.
Topics: 1-Methyl-3-isobutylxanthine; Amrinone; Animals; Anti-Ulcer Agents; Cilostazol; Colforsin; Dipyridamo | 1999 |